Edition:
India

Versartis Inc (VSAR.OQ)

VSAR.OQ on NASDAQ Stock Exchange Global Select Market

1.95USD
2:29am IST
Change (% chg)

$-0.03 (-1.27%)
Prev Close
$1.98
Open
$1.95
Day's High
$1.98
Day's Low
$1.85
Volume
117,065
Avg. Vol
240,150
52-wk High
$24.00
52-wk Low
$1.65

Chart for

About

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's first indication for somavaratan is pediatric GHD. The Company may develop... (more)

Overall

Beta: 2.44
Market Cap(Mil.): $94.42
Shares Outstanding(Mil.): 35.63
Dividend: --
Yield (%): --

Financials

BRIEF-Versartis Inc Says Board Appointed Jay Shepard, CEO, To Position Of Principal Financial Officer

* VERSARTIS INC SAYS ‍ON NOV 28, 2017, BOARD APPOINTED JAY SHEPARD, CEO, TO POSITION OF PRINCIPAL FINANCIAL OFFICER, EFFECTIVE DEC 1, 2017 - SEC FILING​ Source text (http://bit.ly/2A3BTve) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

05 Dec 2017

BRIEF-Versartis hires Cowen to assist in evaluating potential strategic transactions

* Versartis hires Cowen to assist in evaluating potential strategic transactions

27 Oct 2017

BRIEF-Versartis reports Q3 loss $1.40/shr

* Versartis reports third quarter 2017 financial results and provides corporate update

27 Oct 2017

Versartis growth hormone drug fails key study, shares sink

Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

22 Sep 2017

Versartis growth hormone drug fails key study, shares sink

Sept 21 Versartis Inc said its experimental drug for the treatment of growth hormone deficiency in children did not meet the main goal of a late-stage study, sending its shares tanking 85 percent.

22 Sep 2017

BRIEF-Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

* Versartis announces phase 3 Velocity trial of somavaratan in pediatric growth hormone deficiency did not meet primary endpoint

22 Sep 2017

BRIEF-Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​

* Versartis Inc - files for mixed shelf offering of up to $500 million - SEC filing‍​ Source text: (http://bit.ly/2vdEZZz) Further company coverage:

08 Aug 2017

BRIEF-Versartis reports Q2 loss per share $1.04

* Q2 earnings per share view $-0.84 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

28 Jul 2017

Earnings vs. Estimates